Novel Drug Targeting Leukemia Cells Enters Clinical Trial

Researchers at the University of California, San Diego School of Medicine have launched a phase 1 human clinical trial to assess the safety and efficacy of a new monoclonal antibody for patients with chronic lymphocytic leukemia (CLL), the most common form of blood cancer in adults. … Read the full story from the UC San Diego Newsroom


A team led by Dr. Thomas Kipps developed the new antibody, known as cirmtuzumab or UC-961. The work was conducted and supported by a California Institute for Regenerative Medicine HALT grant to co-principal investigators Dennis Carson, MD, and Catriona Jamieson, PhD, MD.

Dr. Thomas Kipps

Catriona H. M. Jamieson, MD, PhDDennis Carson, MD

L to R: Drs. Kipps, Jamieson and Carson.

Study Finds Potential New Drug Therapy for Crohn’s Disease

Ustekinumab Induces, Sustains Clinical Response in Patients

Ustekinumab, an antibody proven to treat the skin condition psoriasis, has now shown positive results in decreasing the debilitating effects of Crohn’s Disease, according to researchers at the University of California San Diego, School of Medicine. The study will appear in the October 18, 2012 issue of the New England Journal of MedicineRead the full story from the UCSD Newsroom


Dr. William J. SandbornThe principal investigator of the study is Dr. William J. Sandborn, professor of medicine and chief of the Division of Gastroenterology at UCSD.  |  Read his academic profile  |  Read his clinical profile

Read the report of the study in the New England Journal of Medicine (full text UCSD only)

Citation of study report:  Sandborn WJ, Gasink C, Gao L-L, Blank MA, Johanns J, Guzzo C, Sands BE, Hanauer SB, Targan S, Rutgeerts P,  Ghosh S, de Villiers WJS, Panaccione R, Greenberg G, Schreiber S, Lichtiger S, Feagan BG for the CERTIFI Study Group. N Engl J Med 2012; 367:1519-1528 October 18, 2012 DOI: 10.1056/NEJMoa1203572

HIV Prevention in a Pill

UC San Diego researchers receive $5.6 million grant to test if they can keep high-risk individuals from becoming infected with virus that causes AIDS

Last year marked the 30th anniversary of the first clinical reports of AIDS, a then-mysterious and invariably fatal disease. Patients diagnosed with an HIV infection faced a looming death sentence. Most had just months to live…. Read the full story from the UCSD Newsroom


AIDS ribbon
One of three UC campuses in the project, UC San Diego will receive $5.6 million over four years. The lead investigator for UC San Diego is Dr. Richard Haubrich, professor in the Division of Infectious Diseases and Antiviral Research Center.

More about the project:

UC San Diego Selected as Study Site for National Research Network

27 institutions looking for ways to boost immune system to fight cancer

The University of California, San Diego School of Medicine is among 27 research institutions selected across North America to be a part of the Cancer Immunotherapy Trials Network (CITN), funded by the National Cancer Institute (NCI). The CITN will establish a network of top academic immunologists to conduct multicenter research on agents that boost patients’ own immune systems to fight their cancer. … Read the full story from the UCSD Newsroom

Dr. Thomas Kipps, pictured above, is principal investigator of the UC San Diego CITN study site. Thomas J. Kipps, MD, PhD, is Professor of Medicine in the Division of Hematology-Oncology and deputy director of the UC San Diego Moores Cancer Center. He holds the Evelyn and Edwin Tasch Chair in Cancer Research. Read more about the Cancer Immunotherapy Trials Network.

UC San Diego Researcher Awarded $5.3 Million for Breast Cancer Survivorship Study

Dr. Barbara A. Parker is an investigator in the new clinical trial described in “UC San Diego Researcher Awarded $5.3 Million for Breast Cancer Survivorship Study” from the UCSD Newsroom.

Barbara A. Parker, M.D., Medical Director of Oncology Services for the Moores UCSD Cancer Center, is Professor of Clinical Medicine in the Division of Hematology-Oncology.

Dr. Lyudmila Bazhenova Leads UCSD Clinical Trials of Promising New Lung Cancer Treatment

The Moores UCSD Cancer Center’s clinical trials of a promising new lung cancer treatment are the subject of the UCSD Newsroom story, “New Lung Cancer Drug Shows Dramatic Results for Shrinking Tumors.”

Dr. Lyudmila Bazhenova is principal investigator for the clinical trials underway at UCSD. Lyudmila Bazhenova, M.D., is Assistant Professor of Medicine in the Division of Hematology-Oncology and Medical Director of the Infusion Center at Moores UCSD Cancer Center.

Cancer Center Evaluating New Treatment for Chronic Lymphocytic Leukemia

Dr. Januario E. CastroMoores UCSD Cancer Center investigators have begun a clinical trial of a new treatment for chronic lymphocytic leukemia.

The study, a Phase I safety trial, is enrolling selected patients whose leukemia has resisted initial treatment or who have a particular chromosomal abnormality.

The study is headed by Dr. Januario E. Castro and employs a new leukemia vaccine that was developed from the work of Dr. Thomas J. Kipps.

Januario E. Castro, M.D., is Assistant Professor of Medicine in the Division of Bone Marrow Transplantation.

Thomas J. Kipps, M.D., Ph.D., is Professor of Medicine in the Division of Hematology-Oncology and Deputy Director for Research at the Moores UCSD Cancer Center.

Read the full story
from UC San Diego
Health Sciences Communications

More Information:

Lung Cancer Vaccine Trial Begins at Cancer Center

The Moores UCSD Cancer Center has started enrolling eligible patients in a trial of a new vaccine for lung cancer.

Called Lucanix™, the vaccine is designed to help a patient’s immune system fight the tumor. It was developed by a local biotechnology company.

The chief investigator in the study is Lyudmila Bazhenova, M.D., Assistant Clinical Professor of Medicine in the Division of Hematology-Oncology. Dr. Bazhenova directs the Lung Cancer Unit at the Cancer Center.

Read the full story
from UC San Diego
Health Sciences Communications

Learn more about
the Lucanix™ trial

More Information

Translational Stem-Cell Research: Potential New Treatment for Blood Disorders Now in Clinical Trial

Dr. Catriona M. H. Jamieson and colleagues are performing the first clinical trial of a promising new treatment that was identified in the laboratory only last year.

The treatment may offer new hope to individuals who have myeloproliferative disorders (MPDs). MPDs can evolve into leukemia.

Catriona M. H. Jamieson, M.D., Ph.D., is Director for Stem Cell Research at the Moores UCSD Cancer Center. She is Assistant Professor of Medicine in the Division of Hematology-Oncology.

The findings that led to the clinical trial were published in Cancer Cell in April 2008. Read the report

Read the full story from UC San Diego Health Sciences Communications

More Information: